Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT05993442

Optimising Kangaroo Care to Reduce Neonatal Severe Infection/Sepsis and Resistant Bacterial Colonisation Among High-risk Infants in NICU.

Optimising Kangaroo Care to Reduce Neonatal Severe Infection/Sepsis and Resistant Bacterial Colonisation Among High-risk Infants in NICU. — Recruiting • Non-phase study • Infectious Disease • NCT05993442.

📅 25 Mar 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT05993442
Sponsor
PENTA Foundation
Start
2024-05-28
ClinicaliQ Trial Snapshot
  • Optimising Kangaroo Care to Reduce Neonatal Severe Infection/Sepsis and Resistant Bacterial Colonisation Among High-risk Infants in NICU. — Recruiting • Non-phase study • Infectious Disease • NCT05993442.
  • NeoDeco is a pragmatic, multicenter, parallel-group, cluster-randomised hybrid effectiveness-implementation trial designed to evaluate the impact of implementing optimised Kangaroo Care (KC) at the unit level compared to standard care in high-technology neonatal units. The trial includes a baseline period, a wash-in phase,….
  • Sponsor: PENTA Foundation.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

NeoDeco is a pragmatic, multicenter, parallel-group, cluster-randomised hybrid effectiveness-implementation trial designed to evaluate the impact of implementing optimised Kangaroo Care (KC) at the unit level compared to standard care in high-technology neonatal units. The trial includes a baseline period, a wash-in phase, and a staggered randomisation approach. The primary focus of the NeoDeco study is on high-risk preterm infants born at less than 32 weeks' gestational age, a population particularly vulnerable to hospital-acquired infections and sepsis during their initial hospital stay. By investigating hospital-acquired infections specifically, the study targets the…

Eligibility Snapshot
  • Site level 1a. Neonatal unit that provide routinely cares for extremely premature infants (

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Pregnancy vaccine reduces baby hospital admissions for RSV by 80%
Infectious Disease · BBC Health · 17 Apr 2026
Maternal RSV vaccination reduces infant hospitalisation risk by 80%, offering significant protection against severe lower respiratory tract infection in the first months…
View brief →
Clinical Brief
Travellers reminded to take precautions to avoid infections abroad this summer
Infectious Disease · UKHSA · 14 Jul 2026
Dengue and Zika cases imported into the UK continue to rise seasonally; clinicians should maintain heightened suspicion for these infections in patients…
View brief →
Clinical Brief
RSV maternal vaccine cuts baby hospital admissions by up to 85%
Infectious Disease · UKHSA · 17 Apr 2026
RSV maternal vaccination during pregnancy reduces hospital admissions in infants by up to 85%, with largest protective effect in premature babies, according…
View brief →
Clinical Brief
Nearly 400 antibiotic-resistant infections each week in 2024
Infectious Disease · UKHSA · 29 Jun 2026
Antibiotic resistance remains a significant burden with ~400 resistant infections weekly in 2024, despite NHS prescribing falling below pre-pandemic levels Private sector…
View brief →
Clinical Brief
What is meningitis B and why is a vaccine only being offered to some teenagers?
Infectious Disease · BBC Health · 12 Jun 2026
Meningitis B Vaccine: Key Takeaways for Clinical Practice Limited NHS eligibility: Meningitis B vaccine is not routinely offered to all teenagers; only…
View brief →
Clinical Brief
Newborn ICU admissions drop 50% in first full year of RSV maternal vaccine programme
Infectious Disease · UKHSA · 12 Aug 2026
RSV maternal vaccination programme has achieved a 50% reduction in neonatal ICU admissions in its first full year of implementation, demonstrating significant…
View brief →